Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Zolbetuximab + CAPOX versus CAPOX in first-line treatment of claudin18.2+/HER2– advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study.
Authors
Manish A. Shah
Weill Cornell Medical College, New York, NY
Manish A. Shah , Jaffer A. Ajani , Salah-Eddin Al-Batran , Yung-Jue Bang , Daniel V.T. Catenacci , Peter C. Enzinger , David H. Ilson , Sunnie S. Kim , Florian Lordick , Kohei Shitara , Eric Van Cutsem , Ahsan Arozullah , Jeffrey J. Raizer , Jung Wook Park , Rui-hua Xu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03653507
DOI
10.1200/JCO.2022.40.4_suppl.TPS365
Abstract #
TPS365
Poster Bd #
M3
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin 18.2+/HER2–advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW.
First Author: Manish A. Shah
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Prevalence of claudin 18.2 (CLDN18.2) and the association of biomarkers with clinical activity in patients with gastric or gastroesophageal adenocarcinoma (G/GEJa) treated with zolbetuximab.
First Author: Diarmuid Martin Moran
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy versus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015.
First Author: Deirdre Jill Cohen
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Network meta-analysis of global trials of 1L therapies in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.
First Author: Manish A. Shah